![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Revance Therapeutics Inc | NASDAQ:RVNC | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.1806 | 4.80% | 3.9406 | 2.39 | 5.90 | 4.13 | 3.72 | 3.91 | 1,766,715 | 05:00:08 |
Revance Therapeutics, Inc.
|
(Name of Issuer)
|
Common Stock, par value $0.001 per share
|
(Title of Class of Securities)
|
761330109
|
(CUSIP Number)
|
(Name, Address and Telephone Number of Person
|
Authorized to Receive Notices and Communications)
|
October 17, 2023
|
(Date of Event Which Requires Filing of This Statement)
|
CUSIP No. 761330109
|
1
|
NAMES OF REPORTING PERSONS
|
|
|
||
Teoxane SA
|
|
|
|||
|
|
||||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a)
|
☐
|
||
(b)
|
☐
|
||||
|
|
||||
3
|
SEC USE ONLY
|
|
|
||
|
|
|
|||
|
|
||||
4
|
SOURCE OF FUNDS (SEE INSTRUCTIONS)
|
|
|
||
OO; WC
|
|
|
|||
|
|
||||
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
|
|
☐
|
||
|
|
|
|||
|
|
||||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
||
Switzerland
|
|
|
|||
|
|
||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
7
|
SOLE VOTING POWER
|
|
|
|
6,550,800
|
|
|
|||
|
|
||||
8
|
SHARED VOTING POWER
|
|
|
||
0
|
|
|
|||
|
|
||||
9
|
SOLE DISPOSITIVE POWER
|
|
|
||
6,550,800
|
|
|
|||
|
|
||||
10
|
SHARED DISPOSITIVE POWER
|
|
|
||
0
|
|
|
|||
|
|
||||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
||
6,550,800
|
|
|
|||
|
|
||||
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
☐
|
||
|
|
||||
|
|
||||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
|
|
||
7.4%
|
|
|
|||
|
|
||||
14
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
||
CO
|
|
|
|||
|
|
Item 3. |
SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
|
Item 5. |
INTEREST IN SECURITIES OF THE ISSUER
|
Dated: October 24, 2023
|
|||
TEOXANE SA
|
|||
By
|
/s/ Patrice Calvayrac | ||
Name:
|
Patrice Calvayrac | ||
Title: |
Chief Financial Officer |
Trade Date
|
Purchase or Sale
|
Quantity
|
Weighted Average Price
|
Low
Price
|
High
Price
|
10/13/2023
|
Purchase
|
412,166
|
$8.5229
|
$8.33
|
$8.67
|
10/16/2023
|
Purchase
|
242,511
|
$8.8250
|
$8.49
|
$9.02
|
10/17/2023
|
Purchase
|
620,874
|
$9.0019
|
$8.74
|
$9.33
|
10/18/2023
|
Purchase
|
365,455
|
$8.8262
|
$8.695
|
$9.08
|
10/20/2023
|
Purchase
|
463,994
|
$9.4423
|
$9.015
|
$9.87
|
1 Year Revance Therapeutics Chart |
1 Month Revance Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions